Salman Punekar, MD
Research & Publications
Biography
Coauthors
Selected Publications
- AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.Mitchell S, Khan B, Payumo F, Chiorean E, Gahvari Z, Hecht J, Hurwitz M, Leidner R, Lenz H, Pelster M, Punekar S, Schoenfeld A, Zhao D, Vallaster M, Nagorsen D. AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps8650-tps8650. DOI: 10.1200/jco.2024.42.16_suppl.tps8650.
- Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumorsMitchell S, Khan B, Payumo F, Chiorean E, Gahvari Z, Hecht J, Hurwitz M, Leidner R, Lenz H, Pelster M, Punekar S, Schoenfeld A, Zhao D, Vallaster M, Nagorsen D. Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. Cancer Research 2024, 84: ct076-ct076. DOI: 10.1158/1538-7445.am2024-ct076.
- Abstract 3916: TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapyPatel A, Sahu S, Geng K, Punekar S, Stephens J, Deng J, Chen T, Ahronian L, Zhang M, Andersen J, Haines B, Wong K. Abstract 3916: TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy. Cancer Research 2024, 84: 3916-3916. DOI: 10.1158/1538-7445.am2024-3916.
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyNassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.
- Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001Spira A, Starodub A, Arbour K, Sommerhalder D, Wolpin B, Barve M, Garrido-Laguna I, Punekar S, Pelster M, Kar S, Wong J, Lin T, Raman R, Tao L, Salman Z, Wang X, Gustafson W, Hong D. Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001. Molecular Cancer Therapeutics 2023, 22: pr010-pr010. DOI: 10.1158/1535-7163.targ-23-pr010.
- Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinomaDolgalev I, Zhou H, Murrell N, Le H, Sakellaropoulos T, Coudray N, Zhu K, Vasudevaraja V, Yeaton A, Goparaju C, Li Y, Sulaiman I, Tsay J, Meyn P, Mohamed H, Sydney I, Shiomi T, Ramaswami S, Narula N, Kulicke R, Davis F, Stransky N, Smolen G, Cheng W, Cai J, Punekar S, Velcheti V, Sterman D, Poirier J, Neel B, Wong K, Chiriboga L, Heguy A, Papagiannakopoulos T, Nadorp B, Snuderl M, Segal L, Moreira A, Pass H, Tsirigos A. Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma. Nature Communications 2023, 14: 6764. PMID: 37938580, PMCID: PMC10632519, DOI: 10.1038/s41467-023-42327-x.
- 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)Punekar S, Welling T, Randolph Hecht J, Molina J, Smith C, Garon E, Pia Morelli M, Fakih M, Kirtane K, Grierson P, Patel S, Lin Y, Kopetz S, Locke F, Ward J, Lozac’hmeur A, Frigault M, Nikiforow S, Weng W, Specht J, Dragovich T, Vong J, Mardiros A, Liechty K, Go W, Welch J, Ng E, Maus M, Maloney D, Simeone D. 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH). 2023, a724-a725. DOI: 10.1136/jitc-2023-sitc2023.0634.
- EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR SubtypeLiu Y, Bi J, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype. Journal Of Thoracic Oncology 2023, 18: s655-s656. DOI: 10.1016/j.jtho.2023.09.1254.
- 713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutationDagogo-Jack I, Dowlati A, Guo R, Awad M, Swalduz A, Calvo E, Garcia V, Adjei A, Lorusso P, Punekar S, Leal T, Yap T, Italiano A, Novotny W, Tankersley C, Rowe S, Paris G, Sun W, Spira A, Besse B. 713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation. Annals Of Oncology 2023, 34: s493-s494. DOI: 10.1016/j.annonc.2023.09.1899.
- 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)Arbour K, Punekar S, Garrido-Laguna I, Hong D, Wolpin B, Pelster M, Barve M, Starodub A, Sommerhalder D, Chang S, Zhang Y, Salman Z, Wang X, Gustafson C, Spira A. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s458. DOI: 10.1016/j.annonc.2023.09.1838.
- Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.Punekar S, Weber J. Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out. Clinical Cancer Research 2022, 28: 5007-5009. PMID: 36161479, DOI: 10.1158/1078-0432.ccr-22-2427.
- The current state of the art and future trends in RAS-targeted cancer therapiesPunekar S, Velcheti V, Neel B, Wong K. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology 2022, 19: 637-655. PMID: 36028717, PMCID: PMC9412785, DOI: 10.1038/s41571-022-00671-9.
- Immunotherapy in non-small cell lung cancer: Past, present, and future directionsPunekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.
- PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.Shu F, Punekar S, Velcheti V, Sanmamed M, Wang J. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy. Clinical Cancer Research 2022, 28: 3182-3184. PMID: 35648093, DOI: 10.1158/1078-0432.ccr-22-0541.
- Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis.Barbaro A, Siskin M, Grello C, Hernandez A, Dublin J, Breslin S, Punekar S, Velcheti V. Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2022, 40: e21120-e21120. DOI: 10.1200/jco.2022.40.16_suppl.e21120.
- Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal CancerPunekar S, Griffin M, Masri L, Roman S, Makarov D, Sherman S, Becker D. Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer. American Journal Of Clinical Oncology 2021, 44: 597-602. PMID: 34753883, DOI: 10.1097/coc.0000000000000875.
- Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic CancerPunekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.
- Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanomaShah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.
- The Segmentation of Neuroendocrine Neoplasms According to HistologyPunekar S, Becker D. The Segmentation of Neuroendocrine Neoplasms According to Histology. American Journal Of Clinical Oncology 2020, 44: 43-43. PMID: 33337644, DOI: 10.1097/coc.0000000000000776.
- Expanding the Role of Immunotherapy to Limited-Stage SCLCPunekar S, Shum E. Expanding the Role of Immunotherapy to Limited-Stage SCLC. Journal Of Thoracic Oncology 2020, 15: 1806-1808. PMID: 33246593, DOI: 10.1016/j.jtho.2020.09.021.
- Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER DatabasePunekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.
- Diabetes mellitus and colorectal carcinoma outcomes: a meta-analysisBecker D, Iyengar A, Punekar S, Kaakour D, Griffin M, Nicholson J, Gold H. Diabetes mellitus and colorectal carcinoma outcomes: a meta-analysis. International Journal Of Colorectal Disease 2020, 35: 1989-1999. PMID: 32564124, DOI: 10.1007/s00384-020-03666-z.
- Association of socioeconomic status and molecular testing in stage IV colorectal cancer.Punekar S, Griffin M, Masri L, Makarov D, Sherman S, Becker D. Association of socioeconomic status and molecular testing in stage IV colorectal cancer. Journal Of Clinical Oncology 2020, 38: e19023-e19023. DOI: 10.1200/jco.2020.38.15_suppl.e19023.
- Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.Cytryn S, Punekar S, Tenet M, Ullah T, Wang B, Goldberg J, Velcheti V, Wong K, Chachoua A, Shum E, Sabari J. Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib. Journal Of Clinical Oncology 2020, 38: e21679-e21679. DOI: 10.1200/jco.2020.38.15_suppl.e21679.
- Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivative‐Mediated Intraperitoneal Photodynamic Therapy in a Canine ModelCramer G, Lewis R, Gymarty A, Hagan S, Mickler M, Evans S, Punekar S, Shuman L, Simone C, Hahn S, Busch T, Fraker D, Cengel K. Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivative‐Mediated Intraperitoneal Photodynamic Therapy in a Canine Model. Photochemistry And Photobiology 2020, 96: 684-691. PMID: 32119123, DOI: 10.1111/php.13247.
- Chapter 1 Mechanisms of Cancer-Directed TherapiesPunekar S. Chapter 1 Mechanisms of Cancer-Directed Therapies. 2020, 1-2. DOI: 10.1016/b978-0-323-67241-2.00001-x.
- Chapter 4 Cancer Treatment-Related ThrombocytopeniaPunekar S. Chapter 4 Cancer Treatment-Related Thrombocytopenia. 2020, 17-20. DOI: 10.1016/b978-0-323-67241-2.00004-5.
- Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.Punekar S, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors. Journal Of Clinical Oncology 2019, 37: e15696-e15696. DOI: 10.1200/jco.2019.37.15_suppl.e15696.
- Novel Therapeutics Affecting Metabolic PathwaysPunekar S, Cho D. Novel Therapeutics Affecting Metabolic Pathways. American Society Of Clinical Oncology Educational Book 2019, 39: e79-e87. PMID: 31099667, DOI: 10.1200/edbk_238499.
- Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA ProgressionBECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.
- Esophageal perforation caused by edible foreign bodies: A systematic review of the literatureAronberg RM, Punekar SR, Adam SI, Judson BL, Mehra S, Yarbrough WG. Esophageal perforation caused by edible foreign bodies: A systematic review of the literature. The Laryngoscope 2014, 125: 371-378. PMID: 25155167, DOI: 10.1002/lary.24899.
- Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural MesotheliomaFriedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.
- Concurrent segmentation of the prostate on MRI and CT via linked statistical shape models for radiotherapy planningChowdhury N, Toth R, Chappelow J, Kim S, Motwani S, Punekar S, Lin H, Both S, Vapiwala N, Hahn S, Madabhushi A. Concurrent segmentation of the prostate on MRI and CT via linked statistical shape models for radiotherapy planning. Medical Physics 2012, 39: 2214-2228. PMID: 22482643, PMCID: PMC3337664, DOI: 10.1118/1.3696376.
- Thrombospondin 1 and Its Mimetic Peptide ABT-510 Decrease Angiogenesis and Inflammation in a Murine Model of Inflammatory Bowel DiseasePunekar S, Zak S, Kalter V, Dobransky L, Punekar I, Lawler J, Gutierrez L. Thrombospondin 1 and Its Mimetic Peptide ABT-510 Decrease Angiogenesis and Inflammation in a Murine Model of Inflammatory Bowel Disease. Pathobiology 2008, 75: 9-21. PMID: 18334835, DOI: 10.1159/000113790.